Cybrexa’s pipeline aims to combat breast, ovarian, non-small cell lung cancer and a range of other tumors. Its assets are built on Cybrexa’s alphalex technology platform, which enables intracellular delivery of potent anticancer treatments.

CBX-12, the company's lead product, is an alphalex conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 has potential synergy with PD-1 inhibitors and other immuno-oncology drugs.